Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance

References

• Druker BJ, O’Brien SG, Cortes J, et al. Chronic myelogenous leukemia. Hematology Am Soc Hematol Educ Program 2002: 111–135.
   PubMedGoogle Scholar
• Koca E, Haznedaroglu IC. Imatinib mesylate and the management of chronic myeloid leukemia (CML). Turk J Hematol 2005;2:161–172.
   Google Scholar
• Savage DG, Antman KH. Imatinib mesylate--a new oral targeted therapy. N Engl J Med 2002;346:683–693.
   PubMed Web of Science ®Google Scholar
• Bonhoure E, Lauret A, Barnes DJ, et al. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. Leukemia 2008;22:971–979.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542–2551.
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531–2541.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129–141.
   PubMed Web of Science ®Google Scholar
• O’Hare T, Walters DK, Deininger MW, et al. AMN107: tightening the grip of imatinib. Cancer Cell 2005;7:117–119.
   PubMed Web of Science ®Google Scholar
• Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009;27:4204–4210.
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251–2259.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190–2196.
   PubMed Web of Science ®Google Scholar
• Ceylan C, Camgoz A, Baran Y. Macromolecular changes in nilotinib resistant K562 cells; an in vitro study by Fourier transform infrared spectroscopy. Technol Cancer Res Treat 2012;11: 333–344.
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Berger U, Pfirrmann M, et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007;109:4686–4692.
   PubMed Web of Science ®Google Scholar
• Walz C, Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 2006;57:145–164.
   PubMed Web of Science ®Google Scholar
• Deininger M. Resistance to imatinib: mechanisms and management. J Natl Compr Canc Netw 2005;3:757–768.
   PubMedGoogle Scholar
• Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96:1070–1079.
   PubMed Web of Science ®Google Scholar
• Baran Y, Ural AU, Gunduz U. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology 2007;12:497–503.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Hayette S, Lagarde V, et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 2008;68:9809–9816.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000;95:3498–3505.
   PubMed Web of Science ®Google Scholar
• Wang Y, Cai D, Brendel C, et al. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood 2007;109:2147–2155.
   PubMed Web of Science ®Google Scholar
• Reed JC. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 2008;111:3322–3330.
   PubMed Web of Science ®Google Scholar
• Dai Y, Rahmani M, Corey SJ, et al. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004;279: 34227–34239.
   PubMed Web of Science ®Google Scholar
• Zamzami N, Brenner C, Marzo I, et al. Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene 1998;16:2265–2282.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103:4396–4407.
   PubMed Web of Science ®Google Scholar
• Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007;21:926–935.
   PubMed Web of Science ®Google Scholar
• Dohse M, Scharenberg C, Shukla S, et al. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos 2010;38:1371–1380.
   PubMed Web of Science ®Google Scholar
• Brendel C, Scharenberg C, Dohse M, et al. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007;21:1267–1275.
   PubMed Web of Science ®Google Scholar
• Hegedus C, Truta-Feles K, Antalffy G, et al. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: Implications for the emergence and reversal of cancer drug resistance. Biochem Pharmacol 2012;84: 260–267.
   PubMed Web of Science ®Google Scholar
• Shen T, Kuang YH, Ashby CR, et al. Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PLoS One 2009;4:e7520(1–9).
   Web of Science ®Google Scholar
• Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004;4:604–616.
   PubMed Web of Science ®Google Scholar
• Sobue S, Iwasaki T, Sugisaki C, et al. Quantitative RT-PCR analysis of sphingolipid metabolic enzymes in acute leukemia and myelodysplastic syndromes. Leukemia 2006;20:2042–2046.
   PubMed Web of Science ®Google Scholar
• French KJ, Schrecengost RS, Lee BD, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003;63:5962–5969.
   PubMed Web of Science ®Google Scholar
• Li QF, Wu CT, Guo Q, et al. Sphingosine 1-phosphate induces Mcl-1 upregulation and protects multiple myeloma cells against apoptosis. Biochem Biophys Res Commun 2008;371:159–162.
   PubMed Web of Science ®Google Scholar
• Baran Y, Salas A, Senkal CE, et al. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem 2007;282:10922–10934.
   PubMed Web of Science ®Google Scholar
• Baran Y, Bielawski J, Gunduz U, et al. Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation. J Cancer Res Clin Oncol 2011;137:1535–1544.
   PubMed Web of Science ®Google Scholar
• Liu YY, Han TY, Giuliano AE, et al. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 1999;274:1140–1146.
   PubMed Web of Science ®Google Scholar
• Venkataraman K, Futerman AH. Do longevity assurance genes containing Hox domains regulate cell development via ceramide synthesis?FEBS Lett 2002;528:3–4.
   PubMed Web of Science ®Google Scholar